Partners | Research Centres
Josep Carreras LEUKAEMIA Research Institute (IJC)
About the IJC
The IJC came into existence in November 2010 as a result of a link-up between the Josep Carreras Foundation and the Generalitat de Catalunya (Government of Catalonia).
The Institute forms part of the network of Research Centres of Catalonia (CERCA), in addition to the competitive funding its researchers obtain from publicly announced subsidies (from the Carlos III Health Institute, Spanish Association Against Cancer (AECC), amongst others) and from research projects for private promoters.
The IJC has three independent and coordinated scientific campuses: the Hospital Clínic-UB Campus, located at the University of Barcelona (UB) Faculty of Medicine, at Barcelona's Hospital Clínic; the Catalan Institute of Oncology/Germans Trias i Pujol Campus in Badalona, located near the Catalan Institute of Oncology at the Germans Trias i Pujol University Hospital, the Autonomous University of Barcelona (UAB) Germans Trias i Pujol Teaching Unit and the Germans Trias i Pujol Research Institute (IGTP); and thirdly, the Sant Pau Campus and its research foundation, located within the health care facilities of the Hospital de la Santa Creu i Sant Pau, the UAB's Sant Pau teaching unit, and the Sant Pau Biomedical Research Institute (IIBStPau).
It is the mission of the Josep Carreras Leukaemia Research Institute to carry out research into the epidemiological, preventive, clinical, translational and basic aspects of leukaemia and other malignant blood diseases through innovation, in order to find a cure.
The Josep Carreras Leukaemia Research Institute's vision is to be a world-renowned, multi-campus research centre of excellence that contributes towards improved outcomes and a cure for patients suffering from leukaemia and other malignant blood diseases through innovation, sustainability, social responsibility, talent and professional expertise.
Strategic Plan 2018 - 2022
The Josep Carreras Leukaemia Research Institute must have a clearly defined strategic horizon, and it must have an organisational culture that is shared by everyone involved.
The IJC embarks on a new phase and has drawn up a participative and constructive Strategic Plan that sets out the road map to answer the challenges the IJC will have to face in the future.
Drawing up a Strategic Plan represents a very good opportunity to reflect on the road taken so far, the present situation for the IJC and, above all, it is a great opportunity for outlining the future.
The new horizon will make us stronger and better; this strategic process will help us grow qualitatively.
We have to work with our eyes wide open, and we must seek out an organisational and administrative model that will help us be more effective in achieving our mission. And we must be very rigorous, and committed to good administration; working for an Institute that is highly aware of the importance of transparency, ethics and values in its onward struggle against leukaemia.
We can count on fine professionals in various disciplines, and this is indeed a great asset. In this regard I would like to acknowledge the dedication and application shown by the Work Team in drawing up this Plan, and the willingness to continue working together throughout the successive phases.
The IJC has new challenges, and together we have all the energy and enthusiasm to confront them.